AB71. Significance of multidrug resistance gene-related proteins in the postoperative adjuvant chemotherapy for gastric cancer and its prognosis
Pengfei Yu, Xiangdong Cheng, Yian Du, Ling Huang, Ruizeng Dong
Objective: To investigate the expression of multidrug resistance (MDR) gene related to proteins in gastric carcinoma as well as their effects on the prognosis of patients.
Methods: The expression of ToPo II, MRP, GST-π in 119 patients with gastric carcinoma were detected by immunohistochemistry. The expression and its relationship to the pathological data and the prognosis of patients were analyzed.
Results: (I) The expression of ToPo II was associated with the types and differentiation of histology; the positive rate of GST-π expression was related to the gender and the differentiation; there was no relationship between the expression of MRP and the pathological data; (II) positive expression of MRP and GST-π negative expression of ToPo II were seen as three risk factors. All the patients were divided into two groups: the high risk group (≥2 risk factors) and the low risk group (<2 risk factors). The recurrence time of the high risk group was shorter than the low risk group (P<0.05), but there was no significant difference of 1-, 3- and 5-year survival rates between the two groups (P>0.05). The 3 and 5 years survival rates of the patients with or without chemotherapy in the high risk group were 62.1%, 44.8% and 52.0%, 40.0% (P>0.05). The 3 and 5 years survival rates of the patients with or without chemotherapy in the low risk group were 81.2%, 71.9% and 51.5%, 45.5%, the survival rate of the patients with chemotherapy is higher than that of the patients without chemotherapy (P
Conclusions: ToPo II, MRP, GST-π was related to part of the pathological data of patients. The adjuvant chemotherapy based on 5-Fu and platinum can significantly improve the prognosis of patients in the low risk group, but it didn’t show advantages in the high risk group.
Keywords: Multidrug resistance (MDR) gene related proteins; gastric carcinoma; postoperative adjuvant chemotherapy; prognosis
